JPWO2020115257A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020115257A5 JPWO2020115257A5 JP2021532415A JP2021532415A JPWO2020115257A5 JP WO2020115257 A5 JPWO2020115257 A5 JP WO2020115257A5 JP 2021532415 A JP2021532415 A JP 2021532415A JP 2021532415 A JP2021532415 A JP 2021532415A JP WO2020115257 A5 JPWO2020115257 A5 JP WO2020115257A5
- Authority
- JP
- Japan
- Prior art keywords
- coating
- core
- copolymer
- enteric
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011248 coating agent Substances 0.000 claims description 14
- 238000000576 coating method Methods 0.000 claims description 14
- 238000005192 partition Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 239000008199 coating composition Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 230000000112 colonic effect Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims 14
- 238000009472 formulation Methods 0.000 claims 7
- 230000003111 delayed effect Effects 0.000 claims 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18211141.9 | 2018-12-07 | ||
EP18211141.9A EP3662900A1 (en) | 2018-12-07 | 2018-12-07 | Colonic drug delivery formulation |
PCT/EP2019/083912 WO2020115257A1 (en) | 2018-12-07 | 2019-12-05 | Colonic drug delivery formulation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022515340A JP2022515340A (ja) | 2022-02-18 |
JPWO2020115257A5 true JPWO2020115257A5 (pt) | 2023-10-06 |
JP7423629B2 JP7423629B2 (ja) | 2024-01-29 |
Family
ID=64661226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021532415A Active JP7423629B2 (ja) | 2018-12-07 | 2019-12-05 | 結腸ドラッグデリバリー製剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220016037A1 (pt) |
EP (2) | EP3662900A1 (pt) |
JP (1) | JP7423629B2 (pt) |
KR (1) | KR20210100666A (pt) |
CN (1) | CN113164400A (pt) |
AR (1) | AR117281A1 (pt) |
AU (1) | AU2019394740A1 (pt) |
BR (1) | BR112021010913A2 (pt) |
CA (1) | CA3122033A1 (pt) |
EA (1) | EA202191431A1 (pt) |
IL (1) | IL283719A (pt) |
MA (1) | MA54376A (pt) |
WO (1) | WO2020115257A1 (pt) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8812490D0 (en) | 1988-05-26 | 1988-06-29 | Agricultural & Food Res | Delayed release formulations |
GB8926639D0 (en) | 1989-11-24 | 1990-01-17 | Agricultural & Food Res | Delayed release formulations |
US5422121A (en) | 1990-11-14 | 1995-06-06 | Rohm Gmbh | Oral dosage unit form |
US5656290A (en) | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
GB9724186D0 (en) | 1997-11-14 | 1998-01-14 | British Tech Group | Low temperature coatings |
FI20000780A (fi) | 2000-04-03 | 2001-10-04 | Novasso Oy | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi |
GB2367002A (en) | 2000-09-25 | 2002-03-27 | British Sugar Plc | Coating composition |
GB0203421D0 (en) | 2002-02-13 | 2002-04-03 | Alizyme Therapeutics Ltd | Composition |
US7670627B2 (en) | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
ES2759626T3 (es) | 2007-05-07 | 2020-05-11 | Evonik Operations Gmbh | Formas farmacéuticas sólidas que comprenden un recubrimiento entérico con liberación acelerada del fármaco |
EP4011364B1 (en) * | 2011-03-23 | 2023-12-13 | Ironshore Pharmaceuticals & Development, Inc. | Methods and compositions for treatment of attention deficit disorder |
CU24342B1 (es) * | 2012-04-30 | 2018-05-08 | Tillotts Pharma Ag | Formulación de fármaco de liberación retardada |
HUE036187T2 (hu) | 2012-04-30 | 2018-06-28 | Tillotts Pharma Ag | Késleltetett leadású gyógyszerkészítmény |
UA117260C2 (uk) * | 2013-10-29 | 2018-07-10 | Тиллоттс Фарма АГ | Лікарський препарат з відстроченим вивільненням |
EP3413877B1 (en) * | 2016-02-09 | 2021-04-07 | Albireo AB | Oral cholestyramine formulation and use thereof |
-
2018
- 2018-12-07 EP EP18211141.9A patent/EP3662900A1/en active Pending
-
2019
- 2019-12-05 AU AU2019394740A patent/AU2019394740A1/en active Pending
- 2019-12-05 CA CA3122033A patent/CA3122033A1/en active Pending
- 2019-12-05 EP EP19816319.8A patent/EP3890711A1/en active Pending
- 2019-12-05 JP JP2021532415A patent/JP7423629B2/ja active Active
- 2019-12-05 CN CN201980081039.1A patent/CN113164400A/zh active Pending
- 2019-12-05 WO PCT/EP2019/083912 patent/WO2020115257A1/en unknown
- 2019-12-05 EA EA202191431A patent/EA202191431A1/ru unknown
- 2019-12-05 US US17/309,558 patent/US20220016037A1/en active Pending
- 2019-12-05 BR BR112021010913-7A patent/BR112021010913A2/pt unknown
- 2019-12-05 MA MA054376A patent/MA54376A/fr unknown
- 2019-12-05 KR KR1020217020598A patent/KR20210100666A/ko not_active Application Discontinuation
- 2019-12-09 AR ARP190103591A patent/AR117281A1/es unknown
-
2021
- 2021-06-06 IL IL283719A patent/IL283719A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5176017B2 (ja) | 結腸薬物送達製剤 | |
JP6621662B2 (ja) | 遅延放出性薬物製剤 | |
JP2020063290A (ja) | 放出調節コーティングカプセル | |
JP2020063295A (ja) | 放出調節コーティングカプセル | |
CA2679409A1 (fr) | Film monocouche a desintegration rapide pour l'administration buccale de substances actives | |
JP6700220B2 (ja) | 遅延放出性薬物製剤 | |
JPWO2020115257A5 (pt) | ||
US5356634A (en) | Controlled-release delivery system | |
TWI827753B (zh) | 結腸藥物遞送配方 | |
CN1232386A (zh) | 弱酸药物的结肠运送 | |
TWI837237B (zh) | 結腸藥物遞送配方 | |
JP7423629B2 (ja) | 結腸ドラッグデリバリー製剤 | |
JPWO2020115254A5 (pt) | ||
WO2021094697A1 (fr) | Procédé de fabrication d'une composition pharmaceutique à administration orale et à délivrance colonique | |
JPWO2020115255A5 (pt) | ||
WO2003030874A1 (fr) | Composition pharmaceutique destinee a liberer une substance active au niveau du colon | |
TW202033201A (zh) | 製造無還原糖5-asa錠劑核心的方法 | |
Kumar et al. | Polysaccharides Based Colon Specific Drug delivery: A |